Sun Pharma inks global licensing pact with LIB Therapeutics for cholesterol drug Lerodalcibep

Lerodalcibep is a once-monthly PCSK9 inhibitor used to reduce low-density lipoprotein cholesterol (LDL-C) and treat adult patients with hypercholesterolaemia and mixed dyslipidaemia